Back A A A Font Size Receive E-mail Alerts Press Releases

MicroPort® Endovascular Attends SJVF-2017


Shanghai, China – From June 23 to June 25, MicroPort Endovascular (Shanghai) Co., Ltd. ("MicroPort® Endovascular") attended the Sixth Shanghai JiaoTong University Vascular Disease Forum ("SJVF-2017") held in Shanghai. Several renowned vascular surgery experts from home and abroad were invited to deliver speeches to reveal the latest achievement and the development trend of the vascular surgery industry in an all-round way while building a platform of communication for surgeons in attendance.
During the summit forum on June 24, Professor Zaiping Jing of Changhai Hospital of the Second Military Medical University delivered a speech of "new advancement of innovations in China's endovascology." Professor Jing pointed out, the feature of aortic arch anatomy is "double curves plus one peak," in which "double curves" are the basis of pathogenesis, while the "one peak" is the therapeutic basis. China is leading the world in endovascular treatment of aortic arch with techniques such as fenestration, chimney, in-situ fenestrated technique, and branched stent technique. One case in point is Castor™ Branched Aortic Stent-Graft System ("Castor™"), the first successfully translated branched endo-prosthesis involving aortic arch in the world, which is jointly developed by Changhai Hospital and MicroPort® Endovascular. Castor™ is also the world's first branched stent graft system designed for an entirely endovascular treatment of thoracic dissection encroaching the left subclavian artery or the original tear located within 15mm distal to the left subclavian artery. According to Professor Jing, Castor™ had launched a multi-center study involving 11 clinical centers in China and has completed a one-year follow-up which achieved good results. The study is the first perspective, multi-center clinical study for original device in the vascular field.
During the session of iliofemoral artery lesion, Professor Weihao Shi of Huashan Hospital of Fudan University delivered a speech of "the application of unibody branched stent-graft in the treatment of aorioiliac occlusive diseases." Professor Shi said, with the technology advancement, an increasingly more physicians are using endovascular technique to treat aorioiliac occlusive diseases. MicroPort® Endovascular's Aegis™ Bifurcated Stent-Graft System ("Aegis™") is indicated for the treatment of abdominal aortic aneurysm. Its unique designs give it advantages in the treatment of aorioiliac occlusive diseases. For example, the device adopts unibody design based on the philosophy of anatomic fixation, which makes the aortic bifurcation anatomy remain unchanged to avoid hemodynamics disorder. Besides, Aegis™ achieves better late patency (90%) compared to other endovascular techniques, with simpler operation, higher success rate, and lower death rate (1%) in the perioperative period.
In sum, the conference featured hot topics of the vascular surgery field and fully displayed new theories, new technologies, new devices and new applications in the industry. As a domestically developed innovative product, Castor™ successfully caught wide attention from the experts in attendance. MicroPort® Endovascular President Zhenghua Miao said: "Castor™ provides a creative solution that makes the delivery and positioning of unibody branched stent much easier and features low occurrence of endoleak and good patency in branch vessel. We believe Castor™ will provide safer and more effective treatment for patients with aortic diseases involving aortic arch."

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2018 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Coporate Genearal Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6953


[Prev]:MicroPort® Orthopedics Hosts US-Chinese Surgeons Academic Exchange Program
[Next]:Castor™ Gains CFDA Approval